Real-World Study Of The Treatments Following Trastuzumab-Emtansine For Her2-Positive Metastatic Breast Cancer: A Multicentral Cohort Study (Wjog12519b).

Sasagu Kurozumi,Takamichi Yokoe,Kazuki Nozawa,Yukinori Ozaki,Tetsuyo Maeda,Shu Yazaki, Mai Onishi,Akihiro Fujimoto,Sayuka Nakayama,Yuko Tsuboguchi,Tsutomu Iwasa,Hitomi Sakai,Misato Ogata,Mitsuo Terada,Meiko Nishimura,Takuma Onoe,Jun Masuda,Michiko Kurikawa,Mototsugu Shimokawa,Toshimi Takano

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览19

暂无评分

摘要

e13019Background: Since trastuzumab emtansine (T-DM1) was established as a standard treatment option, the treatment strategy of metastatic HER2-positive breast cancer has markedly changed. However,...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要